The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA's ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA's ...

The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's OZEMPIC Approval Heat Up the Chronic Kidney disease Therapeutic market | DelveInsight The FDA's recent approval of OZEMPIC ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug ... disease in adults with type 2 diabetes and chronic kidney disease (CKD). "This approval for Ozempic allows us to more broadly ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

05, 2025 (GLOBE NEWSWIRE) -- As chronic kidney disease (CKD ... following the FDA’s recent label expansion of Novo Nordisk’s Ozempic® to include CKD benefits, reinforcing the drug’s ...